Nov 20, 2012
FDA Sends Letter to Alcon Research Regarding Sales Aid
PharmaLive is reprinting a letter the FDA posted to its website yesterday that the agency sent to Alcon Research regarding a profession sales aid for Patanase Nasal Spray.
Olopatadine - Key patent, SPC, and data exclusivity expiry (7 country ...
This Pipeline Selector report covers Olopatadine Olopatadine indications: Treatment of allergic conjunctivitis Olopatadine innovator: Alcon Examples of information found in this online report include: - Includes key patent publications for 7 countries - Contains SPC protection for every EU state plus patent term extensions in other countries - Data ... (more)
Recent Federal Circuit Nonobviousness Opinions: Alcon v. Apotex
I'm catching up with recent Federal Circuit opinions this week. First up, a trio of precedential opinions involving nonobviousness, a surprisingly hot topic.
Alcon Research, Ltd. v. Apotex Inc.
Writing for the majority in Alcon Research, Ltd. v. Apotex Inc. last Wednesday, Judge Moore took issue with a position advanced by Alcon's counsel that would have essentially allowed a court to rewrite patent claims to preserve validity.